Roche has made its case for BTK inhibitor fenebrutinib as a potential new oral therapy for multiple sclerosis, with a phase 2 readout that it says shows significant improv
Novartis' big-selling IgE inhibitor Xolair has been a mainstay of treatment for chronic spontaneous urticaria (CSU) for many years, but with biosimilars looming the company has been looking
A court in Germany has suspended a trial discussing litigation brought against BioNTech and Pfizer by CureVac alleging patent infringement in connection with their mRNA-ba
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho